Mapping the Disconnect: A Evaluation of Cervical Cancer Care Pathways in the Private Sector in Kenya: A Mixed Methods Study.

Cervical cancer is a disease that begins with a silent infection, a virus passed between people that can, over many years, turn healthy cells into something dangerous. In many parts of the world, this progression is no longer a death sentence because doctors have found ways to catch the virus early or remove the cells before they become cancer. The most reliable way to find this virus is a test that looks directly at the genetic material of the infection, a method that is far more sensitive than older techniques that rely on the naked eye to spot changes. For decades, global health leaders have set a clear goal: to vaccinate young girls against the virus, to screen women regularly so they can be treated if needed, and to ensure that those who are diagnosed receive the care they require. Yet, in many low-income nations, the path to this goal is blocked by a simple, stubborn reality: the best tools are often too expensive or too difficult to reach for the people who need them most.

In Kenya, where this disease claims more lives than any other cancer among women, a team of researchers decided to look closely at the private healthcare sector. These are the clinics and hospitals that many people turn to when they are sick, yet they often operate outside the main government health system. The researchers wanted to understand what was happening inside these private facilities. They asked a straightforward question: are these clinics ready to use the best screening tools available, or are they still relying on older, less accurate methods? To find the answer, the team visited thirty private health facilities across fifteen different counties. They did not just ask questions; they looked at the actual records of what tests had been performed, and they sat down with doctors, nurses, and clinic managers to hear their stories about the daily challenges of trying to save lives with limited resources.

What they found was a landscape of missed opportunities. Despite the availability of advanced technology, only a tiny fraction of these private clinics, just nine percent, were able to offer the gold-standard test that looks for the virus's genetic code. Instead, the vast majority of these facilities relied on a method called visual inspection with acetic acid. This older technique involves applying a simple vinegar solution to the cervix and looking for changes with the naked eye. While this method is cheaper and does not require complex machines, it is not as good at finding the virus early. The researchers discovered that the gap between what is possible and what is happening was driven by money. The advanced test costs more than most patients can afford, and the clinics often lack the funds to buy the necessary equipment or pay for the training their staff need to use it correctly.

The journey a woman takes to get screened is often broken and confusing. Even when a clinic can perform a test, the results can take weeks to arrive, leaving a woman in limbo while the disease potentially spreads. If a test comes back positive, the path to treatment is often unclear. In many of the facilities studied, there was no clear system to guide a patient from the screening room to a specialist who could provide treatment. The researchers heard stories of women being sent away to find money for a referral, only to lose hope and never return. The staff themselves were often unsure of the latest guidelines, with many having received only occasional, ad-hoc training rather than a structured education on how to screen effectively. This lack of knowledge meant that even when a woman did show up for a check-up, she might not receive the right advice on how often she should return or what her specific risks were.

However, the study also uncovered signs of hope and practical solutions that are already working in some places. The researchers found that when clinics partnered with community health promoters—local volunteers who know their neighbors and can knock on doors to share information—more women came forward for screening. These trusted voices helped break down the fear and shame that often keep women away from clinics. Another promising strategy was the use of self-sampling kits, where a woman can collect her own sample in private, without needing a doctor to perform an internal exam. This simple change removed a major barrier for women who felt uncomfortable with the traditional procedure or who lived far from a clinic. Facilities that had trained their staff well and that worked closely with their communities reported much higher rates of women getting screened.

The path forward, according to the researchers, requires a new kind of partnership. They suggest that the government and private companies must work together to lower the cost of the advanced tests, perhaps by subsidizing them so that they become affordable for everyone. They also argue that the system needs to be rebuilt to ensure that once a woman is screened, she is not lost along the way. This means creating clear, direct lines to specialists and ensuring that test results come back quickly. The study does not claim that the problem is solved, but it offers a clear map of where the breaks are in the system. By fixing the financial barriers, training the staff, and using community voices to reach women where they are, Kenya has a real chance to close the gap between the private sector and the goal of eliminating this preventable disease. The tools exist; the challenge is simply to make sure they reach the hands of the women who need them.